MG
ISEE

Michael Gelband’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Michael Gelband’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200,000
Closed -$1.39M – 2742
2020
Q4 		$1.39M Buy
+200,000
New +$1.28M 0.01% 697

Other funds holding ISEE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Michael Gelband's ISEE Position: Q2 2023 in Review

Michael Gelband sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 62,666 shares — an estimated $1.52M sold.

Michael Gelband first reported a position in ISEE in Q4 2019 and held it in 8 quarters. The position peaked at $2.3M in Q3 2022. 256 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.

  • Michael Gelband reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Michael Gelband sold 62,666 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $1.52M.
  • Michael Gelband first reported a position in IVERIC bio, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
  • Michael Gelband's IVERIC bio, Inc. Common Stock position peaked at $2.3M in Q3 2022.
  • 256 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.